Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005949 · ClinicalTrials.gov registry record · Phase 2

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

A Phase 2 study of Recurrent Melanoma and Stage IV Melanoma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
50
Enrollment target
1
Study location

NCT00005949 is a Phase 2 study of Recurrent Melanoma and Stage IV Melanoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, below the 171-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005949, a Phase 2 study of Recurrent Melanoma and Stage IV Melanoma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Phase II trial to study the effectiveness of vaccine therapy plus interleukin-2 in treating patients who have advanced melanoma. Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Melanoma vaccine plus interleukin-2 may kill more cancer cells

Conditions Studied

Recurrent Melanoma Stage IV Melanoma

Interventions

  • OTHER laboratory biomarker analysis
  • BIOLOGICAL aldesleukin
  • BIOLOGICAL gp100:209-217(210M) peptide vaccine

Study Locations (1)

Illinois

  • Cancer and Leukemia Group B - Chicago

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2001-03
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00005949

The ClinicalTrials.gov registry entry for NCT00005949 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 171-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (71% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.

NCT00005949 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT00005949 about?

NCT00005949 is a clinical study titled "Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma". Phase II trial to study the effectiveness of vaccine therapy plus interleukin-2 in treating patients who have advanced melanoma. Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill...

What is the current status of trial NCT00005949?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2001-03.

What conditions does trial NCT00005949 study?

This clinical trial studies the following conditions: Recurrent Melanoma, Stage IV Melanoma.

What interventions are being tested in trial NCT00005949?

The interventions under investigation include: laboratory biomarker analysis (OTHER), aldesleukin (BIOLOGICAL), gp100:209-217(210M) peptide vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00005949?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005949 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Melanoma

All registered trials for this condition

Stage IV Melanoma

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.